** 🇮🇳 India Daybook: BEL Bags Defence Orders, Wockhardt & Lupin Gain USFDA Nods — July 15, 2026

**

📍 ORDER WIN

• Bharat Electronics (BEL): The company has secured fresh contracts for defence electronics, significantly strengthening its order book in the aerospace and defence segment.
• Kirloskar Brothers: Its subsidiary, SPP Pumps, has bagged an order worth GBP 11.7 million from Saipem for vertical pumps and spares, to be executed over the coming months.
• Grasim Industries: The company announced an expansion of its renewable energy footprint, focusing on increasing green energy capacity for captive consumption across its manufacturing units.

📍 EARNINGS

• Tata Elxsi: Reported a 22.6% QoQ decline in net profit to ₹171 crore for Q1. While revenue rose 2.8% to ₹1,021 crore, margins contracted to 19% due to higher operational costs.
• L&T Technology Services (LTTS): Q1 net profit grew 7.4% QoQ to ₹357 crore. Revenue increased by 2.9% to ₹2,940 crore, with margins improving by 47 bps to 15.68%.
• Signature Global: Pre-sales for Q1 FY27 rose 25% QoQ to ₹1,970 crore. The company also announced a new collaboration with Italy's Tonino Lamborghini for luxury branded residences.
• Anand Rathi Share & Stock Brokers: Consolidated net profit for Q1 fell 43.8% QoQ to ₹23.4 crore. However, the board has approved fundraising of up to ₹500 crore via NCDs.

📍 REGULATORY & USFDA

• Wockhardt: Continues to see positive momentum following USFDA approval for its novel antibiotic 'Zaynich,' targeting complicated urinary tract infections.
• Lupin: Received tentative USFDA approval for generic Enzalutamide tablets, a critical treatment for prostate cancer, marking a major milestone for its oncology portfolio.
• IOL Chemicals & Pharmaceuticals: Received approval from China's NMPA for its Clopidogrel Bisulfate API, facilitating its entry into the high-growth Chinese pharmaceutical market.
• Concord Biotech: Secured USFDA approval for Mycophenolate Mofetil oral suspension, positioning the company to capitalize on the $30 million immunosuppressant market in the US.
• Alembic Pharmaceuticals: Secured final USFDA approval for its generic Dapsone gel (acne treatment) and oseltamivir phosphate oral suspension (influenza treatment).

📍 ACQUISITION & PARTNERSHIP

• Mankind Pharma: Entered into a strategic partnership with Denovo Sciences to utilize AI-powered platforms for drug discovery, aiming to accelerate its R&D pipeline.
• Biocon: Shares may see volatility after Viatris (Mylan Inc.) sold its entire 5.64% stake in the company for approximately ₹3,679 crore through open market transactions.

📍 IPO & LISTING

• Kusumgar IPO: The company is scheduled to debut on the exchanges today, July 15, 2026. Analysts expect a listing at a premium based on strong gray market trends and subscription data.

TAGS: India Daybook, Stocks in News, Corporate News, Stock Market, Company News